Literature DB >> 21780320

MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors.

Peter K Bode1, André Barghorn, Florian R Fritzsche, Marc-Oliver Riener, Glen Kristiansen, Alexander Knuth, Holger Moch.   

Abstract

Melanoma-associated gene C2 (MAGEC2) is a recently identified cancer testis antigen expressed in normal testicular and placental tissue. It has been detected in some human carcinomas, but its expression in primary testicular germ cell tumors is unknown. Immunohistochemistry was used to study MAGEC2 protein in 325 primary testicular germ cell tumors, including 94 mixed germ cell tumors. Seminomatous and non-seminomatous components were separately arranged and evaluated on tissue microarrays. MAGEC2 expression was compared with POU5F1 (OCT3/4), SOX2, SOX17, KIT and TNFRSF8 (CD30). The mouse monoclonal anti-MAGEC2 antibody (clone LX-CT10.5) revealed a nuclear MAGEC2 expression with little or no background staining. MAGEC2 expression was found in 238 of 254 seminomas (94%), but not in embryonal carcinomas (n=89). POU5F1 (OCT3/4) was positive in 97% of seminomas and all embryonal carcinomas. In contrast, KIT was positive in 94% of seminoma but also in 8% of embryonal carcinomas. TNFRSF8 (CD30) and SOX2 were negative in seminoma and positive in embryonal carcinoma (96 and 90%, respectively). SOX17 was positive in 94% of seminoma and negative in embryonal carcinoma. We conclude that MAGEC2 allows a reliable distinction of seminoma from embryonal carcinomas. Therefore, MAGEC2 represents an additional tool for the differential diagnosis of testicular germ cell tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21780320     DOI: 10.1038/modpathol.2011.6

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.

Authors:  Peter J Siska; Romany A N Johnpulle; Alice Zhou; Jennifer Bordeaux; Ju Young Kim; Bashar Dabbas; Naveen Dakappagari; Jeffrey C Rathmell; W Kimryn Rathmell; Alicia K Morgans; Justin M Balko; Douglas B Johnson
Journal:  Oncoimmunology       Date:  2017-03-20       Impact factor: 8.110

Review 2.  [Testicular seminomas. The classical and the less classical ones].

Authors:  P K Bode; H Moch
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

Review 3.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

4.  Frequent PD-L1 expression in testicular germ cell tumors.

Authors:  C D Fankhauser; A Curioni-Fontecedro; V Allmann; J Beyer; V Tischler; T Sulser; H Moch; P K Bode
Journal:  Br J Cancer       Date:  2015-07-14       Impact factor: 7.640

5.  MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.

Authors:  Fan Yang; Xingchun Zhou; Xia Miao; Tao Zhang; Xiaojun Hang; Ru Tie; Nan Liu; Fei Tian; Fuli Wang; Jianlin Yuan
Journal:  Breast Cancer Res Treat       Date:  2014-04-01       Impact factor: 4.872

6.  Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.

Authors:  Qian Zhao; Wen-Ting Xu; Tuluhong Shalieer
Journal:  Dis Markers       Date:  2016-10-24       Impact factor: 3.434

7.  CNV Hotspots in Testicular Seminoma Tissue and Seminal Plasma.

Authors:  Dora Raos; Irena Abramović; Miroslav Tomić; Alen Vrtarić; Tomislav Kuliš; Marijana Ćorić; Monika Ulamec; Ana Katušić Bojanac; Davor Ježek; Nino Sinčić
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.